Wells Fargo Maintains Overweight on Globus Medical, Lowers Price Target to $70
Wells Fargo analyst Larry Biegelsen maintains Globus Medical (NYSE:GMED) with a Overweight and lowers the price target from $80 to $70.
Earnings Scheduled For May 10, 2022
Companies Reporting Before The Bell
• The Middleby (NASDAQ:MIDD) is expected to report quarterly earnings at $2.10 per share on revenue of $935.99 million.
55 Biggest Movers From Friday
Gainers
Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares jumped 100.9% to close at $2.27 on Friday. Vallon Pharmaceuticals engaged Ladenburg Thalmann & Co Inc to evaluate strategic alternatives for the Company to maximize shareholder value.
35 Stocks Moving In Friday’s Mid-Day Session
Gainers
Blueknight Energy Partners, L.P. (NASDAQ: BKEP) shares climbed 38.9% to $4.5701 after the company announced it will be acquired by its general partner Ergon.
Globus Medical Says CEO David Demski To Resign; Board Names Daniel Scavilla As President, CEO Effective Immediately
Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced the resignation of President and Chief Executive Officer, Dave Demski, after nearly 20 years
Wells Fargo Initiates Coverage On Globus Medical with Overweight Rating, Announces Price Target of $80
Wells Fargo analyst Larry Biegelsen initiates coverage on Globus Medical (NYSE:GMED) with a Overweight rating and announces Price Target of $80.
Globus Medical’s Return on Invested Capital Insights
Pulled from Benzinga Pro data, Globus Medical (NYSE:GMED) showed a loss in earnings since Q3, totaling $15.11 million. Sales, on the other hand, increased by 8.84% to $250.02 million during Q4.
Expert Ratings For Globus Medical
Within the last quarter, Globus Medical (NYSE:GMED) has observed the following analyst ratings:
Globus Medical: Q4 Earnings Insights
Globus Medical (NYSE:GMED) reported its Q4 earnings results on Thursday, February 17, 2022 at 04:15 PM.
Here's what investors need to know about the announcement.